Clinical Trial

Liver Damage and Cardiometabolic Disorders in NAFLD

Study acronym: PLINIO
Recruiting
View on ClinicalTrials.gov →
Summary
Liver fibrosis is the most important prognostic factor in patients with non-alcoholic factor disease. Clinical and biological condition, as diabetes or mutation for PNPLA3, are well known factors associated with liver fibrosis onset and progression. However, little is known about biochemical factors predicting liver fibrosis evolution in large NAFLD populations.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2019-07-25.
Trial Details
NCT Number NCT04036357
Lead Sponsor University of Roma La Sapienza
Conditions NAFLD, Liver Fibroses, Cardiovascular Diseases, Cardiovascular Risk Factor
Enrollment 2,000 participants
Start Date 2011-11
Primary Completion 2036-12-31 (estimated)
Study Completion 2036-12-31 (estimated)
Updated on ClinicalTrials.gov 2019-08-16